Clinical Trial Update: Phase 4 Multicenter, Open-label Study on Efficacy and Safety of Apremilast in Moderate-to-severe Psoriasis

View source ↗

Summary

Phase 4 multicenter, open-label trial evaluating the efficacy and safety of apremilast in moderate-to-severe psoriasis. Sponsored by Daewoong Pharmaceutical Co.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Daewoong Pharmaceutical Co. LTD. | Conditions: Psoriasis | Status: NOT_YET_RECRUITING